# GR1803 Injection in Patients With RRMM

> **NCT06952075** · PHASE2 · RECRUITING · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myleoma

## Interventions

- **DRUG:** GR1803

## Key facts

- **NCT ID:** NCT06952075
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-24
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06952075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06952075, "GR1803 Injection in Patients With RRMM". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06952075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*